Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a poor prognosis. No efficacious treatment options are currently available for patients with advanced metastatic disease with disease progression to standard etoposide, doxorubicin, cisplatin and mitotane (EDP-M) the...

Descripción completa

Detalles Bibliográficos
Autores principales: Laganà, M., Grisanti, S., Ambrosini, R., Cosentini, D., Abate, A., Zamparini, M., Ferrari, V.D., Gianoncelli, A., Turla, A., Canu, L., Terzolo, M., Tiberio, G.A.M., Sigala, S., Berruti, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058897/
https://www.ncbi.nlm.nih.gov/pubmed/35272132
http://dx.doi.org/10.1016/j.esmoop.2022.100422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058897/
https://www.ncbi.nlm.nih.gov/pubmed/35272132
http://dx.doi.org/10.1016/j.esmoop.2022.100422

Ejemplares similares